$MDLN (MEDLINE) — 8-K: MDLN Q2 FY26 EPS $0.50 smashes consensus by +55.8%

Adjusted EPS of $0.50 beat the $0.32 consensus by $0.18 (+55.8%). Revenue reached $7,685M, up 11.6% YoY. FY2026 guidance calls for adjusted EBITDA of $3.3B–$3.4B and organic sales growth of 9.0%–10.0%.

Adjusted EPS of $0.50 beat the $0.32 consensus by $0.18 (+55.8%). Revenue reached $7,685M, up 11.6% YoY. FY2026 guidance calls for adjusted EBITDA of $3.3B–$3.4B and organic sales growth of 9.0%–10.0%.